Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gesine Bug

Showing results (131-140 of 165) with videos related to

Pageof 17
Sort By:
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Blood|January 15, 2020
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors failsJohannes Schetelig, Henning Baldauf, Falk Heidenreich, et al.
Haematologica|January 2, 2015
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemiaFelicitas Thol, Michaela Scherr, Aylin Kirchner, et al.
Annals of Hematology|November 16, 2020
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
Annals of Hematology|June 23, 2021
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
British Journal of Haematology|March 23, 2023
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remissionArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Transplantation and Cellular Therapy|May 7, 2025
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and SwitzerlandAlexander Denk, Matthias Alexander Fante, Silke Heidenreich, et al.
Leukemia|August 6, 2025
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblingsJohannes Schetelig, Henning Baldauf, Carina Rave, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Transplantation and Cellular Therapy|June 16, 2026
Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine OutcomeAnnemarie Mohring, Katja Sockel, Christian Thiede, et al.
Pageof 17

Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Blood|January 15, 2020
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors failsJohannes Schetelig, Henning Baldauf, Falk Heidenreich, et al.
Haematologica|January 2, 2015
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemiaFelicitas Thol, Michaela Scherr, Aylin Kirchner, et al.
Annals of Hematology|November 16, 2020
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
Annals of Hematology|June 23, 2021
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study GroupEsther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, et al.
British Journal of Haematology|March 23, 2023
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remissionArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Transplantation and Cellular Therapy|May 7, 2025
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and SwitzerlandAlexander Denk, Matthias Alexander Fante, Silke Heidenreich, et al.
Leukemia|August 6, 2025
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblingsJohannes Schetelig, Henning Baldauf, Carina Rave, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Transplantation and Cellular Therapy|June 16, 2026
Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine OutcomeAnnemarie Mohring, Katja Sockel, Christian Thiede, et al.
Pageof 17